Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
-
The next year, a patient died and his son said it was because of the procedure called ASR (articular surface replacement), though the company behind ASR denies having given it to this patient. ASR, which involves a metal-on-metal implant, was being...
-
ASR, which involves a metal-on-metal implant, was being marketed by DePuy Orthopaedics, a subsidiary of Johnson & Johnson. The US FDA denied it approval in August 2009. From 2004 till then, over 4,700 people in India got the Rs 1 lakh implant. In...
-
This Jan. 22, 2012 photo shows Johnson & Johnson bath products for sale on a store shelf, in Springfield, Ill. Johnson & Johnson said Tuesday that fourth-quarter profit was barely a tenth what it made a year ago as a slew of charges for recalls,... View Photo »
-
The case often cited is the (1982) Tylenol poisoning case. Even though the maker had no direct connection to the poisoning, it responded in an open fashion with a massive recall. Many people say that over-response is an example of how (Tylenol maker Johnson & Johnson) built a perception of responsibilit...
SOURCE: Reno Gazette-Journal -
They entered into a definitive agreement whereby Johnson & Johnson will acquire Synthes for $21.3 billion, with the goal to according to their press release, to create "product development capabilities potential for technology convergence across...
-
In its most recent Q4 2011 earnings call, even though the company started delivering growth after two years, U.S. sales were down 3.4%. The company's positive performance was primarily due to international growth and due to success of new product...
-
McNeil is part of the consumer health business segment at J&J, which is based in New Brunswick, N.J. The company's prescription drug and medicial device divisions each have issued at least two recalls in the last couple years. Reasons for the recalls...
-
William C. Weldon, chairman and CEO of Johnson & Johnson, participates in the APEC CEO Summit in Honolulu, Hawaii November 12, 2011. View Photo »
-
Johnson & Johnson baby products will no longer include phthlates, quaternium-15, and reduce exposure to 1,4 dioxane. But they’ll still be a long way from natural, with ingredients like parabens on their labels.
SOURCE: Examiner.com -
-
Financial terms of the deal with LifeScan, which runs until 2017 and is non-exclusive, were not disclosed. Insulet's OmniPod is a tubeless insulin pump that features just two parts to assist people with diabetes in a non-invasive way. The company...
-
Boring trumps bedazzling As it turns out, dividends have played a role in other recent triumphs of the boring over the bedazzling. During the stock market swoon from October 2007 to March 2009, Johnson & Johnson stock fell only half as much as Google. ...
About Johnson & Johnson
Wikipedia
Johnson & Johnson (NYSE: JNJ) is a global American pharmaceutical, medical devices and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500. Johnson & Johnson is known for its corporate reputation,[citation needed] consistently... Full Article
Related Photos
-
Reuters Pictures
The company logo of Swiss medical devices maker Synthes is pictured in front of it headquarters in Oberdorf April 25, 2011. Johnson & Johnson is to buy Synthes Inc in a deal worth $21.3 billion, its largest ever buy, boosting its orthopaedics franchise and reshaping the medical...
View Photo » -
Reuters Pictures
A general view shows Swiss medical devices maker Synthes' headquarters in Oberdorf, April 25, 2011. Johnson & Johnson is to buy Synthes Inc in a deal worth $21.3 billion, its largest ever buy, boosting its orthopaedics franchise and reshaping the medical technology industry. Picture...
View Photo » -
AP Photo
Traders work on the floor of the New York Stock Exchange Tuesday, April 19, 2011. Markets edged higher after earnings reports from Johnson & Johnson and Goldman Sachs; and an increase in March housing starts each beat expectations.
View Photo » -
AP Photo
Floor official Glenn P. Carel of Barclays Capital, gestures as he talks to visitors on the floor of the New York Stock Exchange Tuesday, April 19, 2011. Markets edged higher after earnings reports from Johnson & Johnson and Goldman Sachs; and an increase in March housing starts each...
View Photo » -
AP Photo
FILE - This Monday, April 18, 2011 file photo shows a Synthes Inc. office complex in West Chester, Pa. Health giant Johnson & Johnson said Wednesday April 27, 2011 it will buy U.S.-Swiss medical device maker Synthes Inc. for US$21.3 billion, greatly increasing its share of the market...
View Photo » -
Reuters Pictures
File photo of power tools made by Swiss medical device company Synthes are displayed in front on their assembly line at the company plant in Oberdorf February 18, 2009. Synthes said April 18, 2011, it was in takeover talks with Johnson & Johnson, after reports the U.S. group is looking...
View Photo » -
Reuters Pictures
File photo of Swiss medical device company Synthes Chairman of the board Hansjoerg Wyss at the annual news conference of his company in Oberdorf, near Basel, February 18, 2009. Synthes said April 18, 2011, it was in takeover talks with Johnson & Johnson, after reports the U.S. group is...
View Photo » -
AP Photo
In this April 15, 2011 photo, a bottle of Johnson's baby powder is displayed in San Francisco. Health care giant Johnson & Johnson said Tuesday, April 19, 2011, sales rebounded but its profit dropped 23 percent in the first quarter, due to higher expenses, costs of recalls and...
View Photo »
Reuters Pictures
The company logo of Swiss medical devices maker Synthes is pictured in front of it headquarters in Oberdorf April 25, 2011. Johnson & Johnson is to buy Synthes Inc in a deal worth $21.3 billion, its largest ever buy, boosting its orthopaedics franchise and reshaping the medical...
View Photo »
